Organon discontinued OG-6219, a non-hormonal endometriosis treatment, following phase 2 failure to improve pelvic pain. The drug was viewed as a key opportunity with a novel mechanism. Concurrently, Vyne Therapeutics halted enrollment in an early-stage psoriasis study amid FDA hold but remains committed to the candidate. Vor Bio secured $175 million in a private placement to advance autoimmune disease therapies after restructuring, indicating resilience amid funding challenges.